AI assistant
Vimta Labs Ltd. Earnings Release 2026
61730_rns_2026-05-06_3d02fd27-29c1-4e94-8190-a071d498ab7d.pdf
Earnings Release
Open in viewerOpens in your device viewer
Vimta Labs Limited
Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657
Vimta
Driven by Quality. Inspired by Science.
VLL\SE\010\2026-27
Date: 06.05.2026
| BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400001.
Scrip Code : 524394 | National Stock Exchange of India Limited,
“Exchange Plaza”, Bandra, Kurla Complex,
Bandra (E), Mumbai – 400051.
Trading Symbol: VIMTALABS |
| --- | --- |
Dear Sir/Madam,
Sub – Press Release – Audited Financial Results – 31st March 2026.
With reference to the subject cited above and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release regarding the announcement of the Annual Audited Financial Results for the fourth quarter and financial year ended 31st March 2026.
This is for your information and records.
Thanking you,
For VIMTA LABS LIMITED
SUJANI
VASIREDDI
Digitally signed by SUJANI VASIREDDI
Date: 2026.05.06
16:33:43 +05'30'
Sujani Vasireddi
Company Secretary and Compliance Officer
Encl: as above.
Plot No. 5, Life Sciences Facility, Neovantage Science & Technology Park Private Limited, Shamirpet, Genome Valley, Turkapally
Medchal-Malkajgiri, Hyderabad-500 101, Telangana, India. T : +91 40 6740 4040 E : [email protected] URL : www.vimta.com
CIN : L24110TG1990PLC011977
PRESS RELEASE
For Immediate dissemination
Vimta
Driven by Quality. Inspired by Science.
Vimta Labs Limited Q4 & FY26 Results
FY26 Revenue at Rs. 4,163 Mn, up 19.5% YoY
EBITDA margins at 35.8%; PAT margin at 18.6%
Hyderabad, May 6, 2026: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter and year ended March 31, 2026.
Financial Results – Q4 & FY26:
| Particulars (Rs. Mn) | Q4 FY26 | Q3 FY26 | QoQ(%) | Q4 FY25 | YoY (%) | FY26 | FY25 | YoY (%) |
|---|---|---|---|---|---|---|---|---|
| Total Income | 1,120 | 1,005 | 11.5% | 961 | 16.6% | 4,163 | 3,482 | 19.5% |
| EBITDA (including other income) | 421 | 344 | 22.3% | 347 | 21.5% | 1489 | 1262 | 18.0% |
| EBITDA Margin | 37.6% | 34.3% | 36.1% | 35.8% | 36.2% | |||
| PAT (continued operations) | 211 | 176 | 20.1% | 183 | 15.2% | 775 | 668 | 16.1% |
| PAT Margin | 18.9% | 17.5% | 19.1% | 18.6% | 19.2% | |||
| Basic EPS | 4.7 | 4.0 | 19.6% | 4.1 | 15.3% | 17.4 | 15.0 | 15.9% |
Note: Vimta Labs sold its Diagnostic and Pathological services business to Thyracare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period
Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said:
"We are pleased to close this fiscal year on a strong note, achieving the highest-ever quarterly revenue of Rs. 1,120 Mn, up by 11.5% YoY. On a full-year basis, we crossed an important milestone and achieved a revenue of Rs. 4,163 Mn. These strong results were driven by the exceptional performance of our Pharma, and Food divisions. Sustained demand across sectors for high-quality research and testing services, coupled with the continued trust and confidence demonstrated by our customers, enabled us to deliver a strong EBITDA margin for the year.
This performance underscores the strength of our diversified service portfolio, operational discipline, and customer-centric approach. As we move forward, we remain focused on expanding capabilities, investing in technology and talent, and strengthening long-term partnerships to drive sustainable growth and value creation for all stakeholders."
Key Result Highlights for the Q4 & FY26:
Q4 FY26
- ☑ Total Income for Q4 FY26 was at Rs. 1,120 Mn
- ☑ EBITDA for Q4 FY26 was Rs. 421 Mn; EBITDA margin was at 37.6%
- ☑ PBT for Q4 FY26 was at Rs. 290 Mn
- ☑ Q4 FY26 PAT was at Rs. 211 Mn; PAT margin was at 18.9%
- ☑ Basic EPS in Q4 FY26 was Rs. 4.7
PRESS RELEASE
For Immediate dissemination
Vimta
Driven by Quality. Inspired by Science.
FY26
- ☑ Total Income for FY26 was at Rs. 4,163 Mn
- ☑ EBITDA for FY26 was Rs. 1,489 Mn; EBITDA margin was at 35.8%
- ☑ PBT for FY26 was at Rs. 1,040 Mn
- ☑ FY26 PAT was at Rs. 775 Mn; PAT margin was at 18.6%
- ☑ Basic EPS in FY26 was Rs. 17.4
Note:
Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period.
ABOUT VIMTA LABS LIMITED:
Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services.
CAUTIONARY STATEMENT:
This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.
For details, please contact:
| Investor Relations at Vimta Labs
Siva Kambhampati
(Chief Financial Officer)
[email protected]
Ernst & Young
Siddesh Chawan
[email protected]
Advait Bhadekar
[email protected] | Registered Office
Plot Number 142, IDA Phase 2, Cherlapally, Hyderabad
Telangana, India. 500051
CIN: L24110TG1990PLC011977
ISIN: INE579C01029
NSE Code: VIMTALABS
BSE CODE: 524394
Website: www.vimta.com |
| --- | --- |